Abstract
Purpose: Taxol represents a new class of anticancer agents with activity against a wide variety of solid tumors. In preclinical systems, its cytotoxicity is schedule dependent with prolonged exposure being more effective. We studied a 120-hour infusion schedule of Taxol in patients with metastatic measurable colorectal carcinoma who had had one prior 5-FU-based chemotherapy. Methods: Patients with measurable metastatic colorectal carcinoma were eligible. Patients had to have normal liver, renal, and bone marrow functions. Written informed consent was obtained from all patients. The starting dose of Taxol was 150 mg/m2 infused over 120-hours in the outpatient setting. Taxol was repeated every 21 days. Results: Fifteen patients were registered. Among 14 evaluable patients, we did not observe any complete or partial response. Major toxicity included myelosuppression and mucositis. There was no treatment-related death. Conclusion: Taxol administered by this schedule was found ineffective in patients with metastatic colorectal carcinoma who had previously received one 5-FU-based chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Parker SL, Tong T, Boldan, Wingo PA: Cancer statistics 1997. Ca Cancer J Clin 47: 5–27, 1997
Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330: 1136–1142, 1994
Leichman CG, Fleming TR, Muggia FM et al.: Phase II study of 5–fluorouracil and its modulation in advanced colorectal cancer: a Southwestern Oncology Group Study. J Clin Oncol 13: 1303–1311, 1995
Poon MA, O'Connell MJ, Moertel CG et al.: Biochemical modulation of fluorouracil evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418, 1988
Shimada Y, Rougier P, Pitot H: Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 32A: S13–17, 1996
Rothenberg ML: The current status of irinotecan (CPT-11) in the United States. Ann NY Acad Sci 803: 272–281, 1996
Wani MC, Taylor HL, Wall ME et al.: Plant antitumor agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from taxus brevifolia. Am Chem Soc 893: 2325–2327, 1971
Parness J, Horwitz SB: Taxol binds to polymerized microtubules in vitro. J Cell Biol 91: 479–487, 1981
Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 50triphosphate or microtubule-associated protein. Biochemistry 20: 3247–3252, 1981
Kumar N: Taxol-induced polymerization of purified tubulin. Mechanism of Action. J Biol Chem 256: 10435–10441, 1981
Rowinsky EK, Donehower RC, Jones RJ et al.: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48: 4093–4100, 1988
Spriggs DR, Tondini C: Taxol administered as a 120–hour infusion. Invest New Drugs 10: 275–278, 1992
Wilson WH, Chabner BA, Bryant Get al.: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13: 381–386, 1995
Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH: Comprehensive criteria for therapy-induced toxicity. Cancer Invest 8: 141–153, 1990
Rowinsky EK, Donehower RC: Paclitaxel (Taxol). New Engl J Med 332: 1004–1014, 195
National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, NCI, Bethesda, MD, September, 1983, pp 6–12
Pazdur R, Lassere Y, Soh LT et al.: Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncology 5: 468–470, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ajani, J.A., Pazdur, R., Dumas, P. et al. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs 16, 175–177 (1998). https://doi.org/10.1023/A:1006093008179
Issue Date:
DOI: https://doi.org/10.1023/A:1006093008179